As a result of therapeutic advances, there is a growing population of survivors of both
Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). A thorough understanding …

Recently, encouraging data provided long-awaited hope for gene therapy as a cure for
sickle cell disease (SCD). Nevertheless, the transient suspension of the bluebird bio gene …

Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of
cytotoxic chemotherapy. Despite major changes in cancer treatment, data describing tAML …

Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence
of second cancers, but the contribution of commonly used frontline therapies to the …

Purpose Previous studies have shown increased risks of second malignancies after non-
Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier …

Lymphoma treatment has evolved to reflect the fact that even when cure is achieved,
significant chronic or late-onset toxi city can vitiate long-term patient outcomes. Previously …

Background Historically, survivors of common lymphoid neoplasms (LNs) had increased
risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML) …

Objective—To determine factors predicting survival in dogs with high-grade multicentric
lymphoma. Design—Retrospective cohort study. Animals—127 dogs with high-grade …

Background Patients with chronic lymphocytic leukemia (CLL) have a higher risk of
developing other malignancies (OMs) compared to the general population. However, the …

Relatively little information is available on the incidence of secondary cancer in non-
Hodgkin's lymphoma. The aim of this long-term follow-up study was to determine the …